XmAb14045

Deaths spur partial hold for Xencor’s CD3 bispecific for leukemia, partnered with Novartis in $2.5B deal
Endpoints
Wed, 02/20/19 - 10:00 am
Xencor
XmAb14045
bispecific antibodies
acute myeloid leukemia